Integrating smoking cessation into HIV care

AIDS Patient Care and STDs

Volumn 24, Issue 3, 2010, Pages 139-140

  Drach, Linda ^a   Holbert, Tim ^a   Maher, Julie ^a   Fox, Victor ^a   Schubert, Stacey ^a   Saddler, Laura Chisholm ^a  

^a OREGON PUBLIC HEALTH DIVISION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; NELFINAVIR; NICOTINE; RITONAVIR; VARENICLINE;

ABSENCE OF SIDE EFFECTS; CIGARETTE SMOKING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MENTAL DISEASE; NICOTINE REPLACEMENT THERAPY; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANTI-HIV AGENTS; BENZAZEPINES; BUPROPION; COMBINED MODALITY THERAPY; DOPAMINE UPTAKE INHIBITORS; GOVERNMENT PROGRAMS; HIV INFECTIONS; HUMANS; NICOTINIC AGONISTS; OREGON; QUINOXALINES; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 77949419006     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0274     Document Type: Letter

References (12)

1. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res 2005;7: 511-522.
2. Niaura R, Shandel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus, AIDS, and smoking cessation: The time is now. Clin Infect Dis 2000; 31:808-812.
3. Palella FJ, Delaney KM, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV Outcomes Study. J Acquir Immune Defic Syndr 2006;43:27-34.
4. Reynolds NR. Cigarette smoking and HIV: More evidence for action. AIDS Educ Prev 2009;21(suppl):106-121.
5. Nahvi S, Cooperman NA. Review: The need for smoking cessation among HIV-positive smokers. AIDS Educ Prev 2009;21(suppl):14-27.
6. Oregon Department of Human Services, Behavioral Risk Factor Surveillance System 2006. Portland, OR: Department of Human Services. www.dhs.state.or.us= dhs=ph=chs=brfs=06=tobacco.pdf (Last accessed October 15, 2009).
7. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: A case series. AIDS 2003;17:638-640.
8. U.S. Food and Drug Administration. Information FDA re-quies new boxed warnings for the smoking cessation drugs Chantix and Zyban. July 1, 2009. www.fda.gov=Drugs=
9. Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: Toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDs 2007;21:458-468.
10. Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV=AIDS. AIDS Patient Care STDs 2007;21:659-666.
11. Cummins SE, Bailey L, Campbell S, et al. Tobacco cessation quitlines in North America: a descriptive study. Tob Control 2007;16(suppl):i9-i15
12. US Department of Health & Human Services, Health Resources & Services Administration, HIV=AIDS Bureau. Ryan White Program Information. http:= = hab.hrsa.gov= treatmentmodernization=adap.htm. (Last accessed October 15, 2009).